Hikal Limited — PPTs, 13-11-2025: Investor Presentation

Hikal's Q2 revenue was ₹319 Cr (down 29% YoY) with a PAT of (₹35) Cr. For H1, revenue stood at ₹699 Cr (down 19% YoY) with a PAT of (₹57) Cr. Performance was impacted by deferments in the Pharmaceutical business following a US FDA warning letter, and muted demand in Crop Protection.

The company is actively executing a robust remediation program to address FDA observations, expecting H2 FY26 to recover the deferred Pharma sales. Strategic diversification into Personal Care and Animal Health is underway, with new products slated for commercialization in H2 FY26 and beyond. Hikal also inaugurated a state-of-the-art High Potency API (HPAPI) lab and a new kilo lab, enhancing its capabilities in niche segments.

Management anticipates a strong recovery in Q3 and Q4, driven by improved demand visibility, higher capacity utilization, and the commercialization of new offerings.